REG - Hutchmed China Ltd - Vesting of awards under Long Term Incentive Plan
HUTCHMED (China) Limited announced the vesting of non-performance based awards under its Long Term Incentive Plan (LTIP) on October 20, 2025. The awards, granted on October 20, 2021, were vested to Dr. Dan Eldar, Ms. Edith Shih, and Professor Tony Mok, each receiving 1,938 American depositary shares (ADS). The transaction was conducted outside a trading venue, and the ADS represents five ordinary shares of US$0.10. HUTCHMED is a biopharmaceutical company focused on cancer and immunological disease therapies.
RNS Number : 0510E Hutchmed (China) Limited 21 October 2025
Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ - Tuesday, October 21, 2025: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan ("LTIP") on October 20, 2021 to the following persons discharging managerial responsibilities were vested on October 20, 2025:-
Award Holder | Number of American depositary shares ("ADS") |
Dr Dan Eldar (Non-executive Director ("NED")) | 1,938 |
Ms Edith Shih (NED) | 1,938 (1) |
Professor Tony Mok (Independent Non-executive Director) | 1,938 |
Note:
(1) These ADSs were not received by Ms Edith Shih, but were received by or for the account of her employer, Hutchison International Limited.
The notifications set out below are provided in accordance with the requirements of the UK Market Abuse Regulation.
(a) Dr Dan Eldar
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name | Dr Dan Eldar | ||||
2 | Reason for the notification | |||||
a) | Position/status | Non-Executive Director | ||||
b) | Initial notification/Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | HUTCHMED (China) Limited | ||||
b) | LEI | 2138006X34YDQ6OBYE79 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | ADS each representing five Ordinary Shares of US$0.10 ADS ISIN: US44842L1035 | ||||
b) | Nature of the transaction | Vesting of awards granted on October 20, 2021 under HUTCHMED's LTIP | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information | N/A | ||||
e) | Date of the transaction | 2025-10-20 | ||||
f) | Place of the transaction | Outside a trading venue |
(b) Professor Tony Mok
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name | Professor Tony Mok | ||||
2 | Reason for the notification | |||||
a) | Position/status | Independent Non-Executive Director | ||||
b) | Initial notification/Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | HUTCHMED (China) Limited | ||||
b) | LEI | 2138006X34YDQ6OBYE79 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | ADS each representing five Ordinary Shares of US$0.10 ADS ISIN: US44842L1035 | ||||
b) | Nature of the transaction | Vesting of awards granted on October 20, 2021 under HUTCHMED's LTIP | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information | N/A | ||||
e) | Date of the transaction | 2025-10-20 | ||||
f) | Place of the transaction | Outside a trading venue |
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.
CONTACTS
| Investor Enquiries | +852 2121 8200 / ir@hutch-med.com |
| Media Enquiries | |
FTI Consulting - | +44 20 3727 1030 / HUTCHMED@fticonsulting.com |
Ben Atwell / Alex Shaw | +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) |
Brunswick - Zhou Yi | +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com |
| Panmure Liberum | Nominated Advisor and Joint Broker |
Atholl Tweedie / Emma Earl / Rupert Dearden | +44 20 7886 2500 |
| Cavendish | Joint Broker |
Geoff Nash / Nigel Birks | +44 20 7220 0500 |
| Deutsche Numis | Joint Broker |
Freddie Barnfield / Jeffrey Wong / Duncan Monteith | +44 20 7260 1000 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END DSHDZMZGGGRGKZM
